

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 71264

Title: Case report and review of dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease.

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05402718

Position: Peer Reviewer

Academic degree: PhD

Professional title: Assistant Professor, Research Associate

Reviewer's Country/Territory: China

Author's Country/Territory: Australia

Manuscript submission date: 2021-09-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-02 00:11

Reviewer performed review: 2021-09-13 09:31

Review time: 11 Days and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

In the present study, Au et al. presented Safety of dual biologic therapy in a patient receiving ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease. A case report and literature review update. Comments for authors. 1. Title, "A case report and literature review update", it is hard to understand. I can't see literature review update. 2. Abstract, "There were no adverse reactions for the duration of treatment", the authors should present the case more gentle. How to proof that "no adverse reactions"? 3. Introduction, "Furthermore, the COVID-19 pandemic presents new challenges in the clinical setting with concerns to the safety of biologic therapy", please supply references. 4. The language is needed to be improved. There are some mistakes for the grammar and language problems. For example, line 113, "stricturing" is a wrong word. 5. Line 140, "Unfortunately, 5 months in to therapy she developed diarrhoea despite having therapeutic levels of vedolizumab of 33 ug/mL", could you please give the discussion for the developed diarrhoea. This should be adverse reactions, which is inconsistent to the point 1. 6. Except CRP, whether there are other indexes, such as inflammatory factors (IL-6), oxygenation index. 7. The ethical approval document is lacked. 8. "Funding, Nil.", please provide the full name of Nil.. 9. There are no figures and tables, this case needs more evidences.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 71264

Title: Case report and review of dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease.

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05852316

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Australia

Manuscript submission date: 2021-09-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-28 01:25

Reviewer performed review: 2021-09-28 02:51

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input type="checkbox"/>] Anonymous [<input checked="" type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

In the present study, Au et al. presented Safety of dual biologic therapy in a patient receiving ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease. A case report and literature review update. Comments for authors

1. The ethical approval document is lacked.
2. Line 112 "A 45-year-old female with a four-month history of newly diagnosed ileal CD " How to diagnose diagnosed ileal CD?. Pathological diagnosis ?
3. Line 147. 148 " To date, the patient has safely received five months of DBT without adverse side-effects." The case Will been taken longer to observe the patient's curative effect.
4. The literature review update isn't been seen in the article
5. Except CRP, whether there are other indexes, such as inflammatory factors (IL-6), oxygenation index. The article is not detailed, The case of the article is too simple. There are no figures and tables, this case needs more evidences.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 71264

Title: Case report and review of dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease.

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05852316

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Australia

Manuscript submission date: 2021-09-01

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2021-11-25 07:48

Reviewer performed review: 2021-11-26 02:00

Review time: 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dual biologic therapy can offer new treatment strategies in patients with Crohn's disease and in patients with different immune-mediated conditions. This case report should be valuable.